Spectral Medical Inc. (TSX: EDT) and its partner Vantive have announced the publication of the full results from the Tigris clinical trial in the prestigious journal The Lancet Respiratory Medicine. The randomized-controlled trial evaluated the efficacy and safety of Polymyxin B Hemoadsorption (PMX) therapy in adult patients suffering from endotoxic septic shock. The published data provides a comprehensive view of patient outcomes, highlighting significant survival benefits and safety profiles over the study period. This peer-reviewed validation is a critical milestone for Spectral Medical, as it reinforces the clinical evidence supporting its innovative PMX treatment. Investors view the publication in a top-tier medical journal as a positive signal for the company's future regulatory and commercial prospects. The Tigris trial results are expected to bolster the medical community's confidence in adopting this therapy for critical care applications.

Sources:globenewswire.comjournals.ekb.egthecvc.canextias.comgist.github.commanilatimes.netbiospace.comtipranks.comaktiencheck.de